Epilepsy and other neurological deficits are common, disabling manifestations of the genetic disorder, tuberous sclerosis complex (TSC). Brain inflammation has been implicated in contributing to epileptogenesis in acquired epilepsy due to brain injury, but the potential role of inflammatory mechanisms in genetic epilepsies is relatively unexplored. In this study, we investigated activation of inflammatory mediators and tested the effects of anti-inflammatory treatment on epilepsy in the Tsc1-GFAP conditional knock-out mouse model of TSC (Tsc1 GFAP CKO mice). Real-time quantitative RT-PCR, immunohistochemistry, and Western blotting demonstrated increased expression of specific cytokines and chemokines, particularly IL-1β and CXCL10, in the neocortex and hippocampus of Tsc1 GFAP CKO mice, which was reversed by treatment with a mammalian target of rapamycin complex 1 (mTORC1) inhibitor. Double-labeling immunohistochemical studies indicated that the increased IL-1β was localized primarily to astrocytes. Importantly, the increase in inflammatory markers was also observed in astrocyte culture in vitro and at 2 weeks of age in Tsc1 GFAP CKO mice before the onset of epilepsy in vivo, indicating that the inflammatory changes were not secondary to seizures. Epicatechin-3-gallate, an inhibitor of IL-1β and CXCL10, at least partially reversed the elevated cytokine and chemokine levels, reduced seizure frequency, and prolonged survival of Tsc1 GFAP CKO mice. These findings suggest that mTOR-mediated inflammatory mechanisms may be involved in epileptogenesis in the genetic epilepsy, TSC.
Introduction
Tuberous sclerosis complex (TSC) is a genetic disorder, characterized by tumor or hamartoma formation in multiple organs (Crino et al., 2006; Orlova and Crino, 2010) . Neurological involvement often accounts for the most disabling symptoms of TSC, including drug-resistant epilepsy, intellectual disability, and autism (Chu-Shore et al., 2010; Holmes et al., 2007) . TSC is caused by mutations in the TSC1 or TSC2 genes, which leads to hyperactivation of the mammalian target of rapamycin complex 1 (mTORC1) pathway and stimulates cell growth and proliferation, promoting tumor growth. The use of mTOR inhibitors represents a rational, proven approach for treating tumors in TSC (Franz et al., 2013; Krueger et al., 2010) .
Although TSC patients can develop brain tumors, the chronic neurological symptoms of epilepsy, intellectual disability, and autism are generally not directly caused by tumor growth per se. Cortical tubers, which represent static, developmental malformations or hamartomas of the brain, may contribute to some of the chronic neurological manifestations of TSC, especially epilepsy. However, there is also accumulating evidence that non-tuber, structurally normal-appearing regions of the brain possess cellular and molecular abnormalities that promote neurological dysfunction (Wong, 2008) .
Independent of tumor growth, the mTORC1 pathway has also been implicated in promoting epilepsy and intellectual disability in TSC patients, and mTOR inhibitors are being tested in clinical trials as potential treatments for these neurological symptoms (Krueger et al., 2013) . Even if mTOR inhibitors are effective against neurological manifestations of TSC, the critical mechanisms downstream from mTORC1 causing epilepsy and neurocognitive dysfunction in TSC are poorly understood. As mTORC1 inhibitors have significant side effects, such as immunosuppression, identification of these downstream mechanisms may lead to more targeted therapies, with more specific efficacy and fewer side effects.
Brain inflammation has been strongly implicated in the pathophysiology of epilepsy and other neurological disorders (Vezzani et al., 2013a, b; Xu et al., 2013) . While activation of inflammatory mechanisms in Abbreviations: ANOVA, analysis of variance; CKO, conditional knock-out; ECG, epicatechin-3-gallate; EEG, electroencephalography; GFAP, glial fibrillary acidic protein; IL-1 β, interleukin-1β; KO, knock-out; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; RT-PCR, reverse transcriptase polymerase chain reaction; SEGA, subependymal giant cell astrocytoma; TSC, tuberous sclerosis complex.
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